

## **LIFECARE ASA: NOTIFICATION OF TRADE - EXERCISE OF WARRANTS**

**Reference is made to the stock exchange announcement by Lifecare ASA (the "Company") dated 2 June 2025 regarding the commencement of the exercise period for 4,193,806 warrants (the "Warrants") issued in connection with the partially underwritten rights issue of new shares in the Company completed in June 2024 (the "Rights Issue").**

Each Warrant gives the holder a right to subscribe for one new share in the Company at an exercise price per share of NOK 5.31681. Warrants that are not exercised to subscribe for new shares before the end of the Exercise Period at 16:30 hours (CEST) on 13 June 2025 will have no value and will lapse without compensation to the holder. Holders of Warrants who do not exercise their Warrants within the Exercise Period may experience a dilution of their shareholding in the Company.

The Company has been informed that Hannibal Invest AS, a company closely related to Hans Hekland, Board member and primary insider of Lifecare ASA, has exercised 1,335 Warrants for the allocation of 1,335 New Shares in the Company at a price per New Share of NOK 5.31681.

Subject to timely payment of the aggregate exercise amount for the new shares on 19 June 2025, the Company expects that the share capital increase pertaining to the issuance of the new shares will be registered with the Norwegian Register of Business Enterprises on or about 24 June 2025 and that shares will be delivered to the VPS accounts of the subscribers to whom they are allocated on or about 25 June 2025.

The shares received upon exercise of Warrants will be listed on Euronext Oslo Børs under ISIN NO0013355859 and ticker code "LIFE". The shares will be listed as soon as the new shares are fully paid, the share capital increase pertaining to the issuance of the new shares has been registered in the Norwegian Register of Business Enterprises, and the new shares have been issued in the VPS.

The shares received upon exercise of Warrants may not be transferred or traded before (i) the new shares have been fully paid, (ii) the share capital increase pertaining to the issuance of the new shares has been registered with the Norwegian Register of Business Enterprises, and (iii) the new shares have been issued in the VPS.

### **About us**

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

**Contacts**

For further information, please contact:

Joacim Holter, CEO, [joacim.holter@lifecare.no](mailto:joacim.holter@lifecare.no), +47 40 05 90 40

Renete Kaarvik, CFO, [renete.kaarvik@lifecare.no](mailto:renete.kaarvik@lifecare.no), +47 94 83 82 42